Psoriasis: A Primer for General Physicians

Psoriasis is a multisystem, polygenic, inflammatory condition that typically causes changes in the skin. Although there is a significant genetic component, environmental factors like infections can have a significant impact on triggering the disease. A major part of the pathogenesis of psoriasis is played by the Interleukin (IL) IL23/IL17 axis along with the immune-related cells mainly macrophages and dendritic cells (DCs). Additionally, the role of various cytokines along with the toll-like receptors has also been pointed out in immunopathogenesis. These have been supported by the efficacy of biological therapies including TNF alpha inhibitors and inhibitors of IL17 and IL23. We have summarized the topical as well as systemic therapies for psoriasis including biologics. The article throws light on a few emerging therapeutic options like modulators of sphingosine 1-phosphate receptor 1 and Rho-associated kinase 2 inhibitors.

Automated summary

Psoriasis is an inflammatory condition that affects the skin and involves various genetic and environmental factors. The Interleukin IL23/IL17 axis and immune-related cells play important roles in its pathogenesis. Biological therapies targeting TNF alpha, IL17, and IL23 have shown effectiveness. The article provides a summary of topical and systemic treatments for psoriasis, including emerging options like sphingosine 1-phosphate receptor 1 modulators and Rho-associated kinase 2 inhibitors.